Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Capital Expenditures came in at $184000.0 in Q1 2026, up 64.29% year-on-year from $112000.0 in Q1 2025, and up 111.49% on a QoQ basis from $87000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Capital Expenditures data on file, last reported at $184000.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures rose 64.29% year-over-year to $184000.0 in Q1 2026; TTM through Mar 2026 was $241000.0, a 38.68% decrease from a year earlier, with the FY2025 full-year figure at $169000.0, down 41.52% from the prior year.
- Capital Expenditures for Q1 2026 stood at $184000.0, up from $87000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for OBIO reached as high as $266000.0 in Q2 2022 and fell as low as -$64000.0 in Q3 2025.
- Historically, Capital Expenditures has averaged $77117.6 across 5 years, with a median of $54000.0 in 2022.
- Across the five-year window, Capital Expenditures surged 3633.33% in 2024 and tumbled 194.12% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $54000.0 in 2022, then slumped by 105.56% to -$3000.0 in 2023, then jumped by 3633.33% to $106000.0 in 2024, then retreated by 17.92% to $87000.0 in 2025, then surged by 111.49% to $184000.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $184000.0 in Q1 2026, $87000.0 in Q4 2025, and -$64000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Orchestra BioMed Holdings | 228.31 Mn | 143.68 Mn | 78,000.00 | 184,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184,000.00 |
| Mar 31, 2026 | 184,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Sep 30, 2025 | -64,000.00 |
| Sep 30, 2025 | -64,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 107,000.00 |
| Jun 30, 2024 | 107,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Dec 31, 2023 | -3,000.00 |